<DOC>
	<DOCNO>NCT01543906</DOCNO>
	<brief_summary>The purpose study : - To evaluate whether 7-day treatment oral QLT091001 improve visual function RP subject autosomal dominant mutation RPE65 . - To evaluate duration visual function improvement ( observe ) RP subject autosomal dominant mutation RPE65 7-day treatment oral QLT091001 . - To evaluate safety oral QLT091001 administer daily 7 day RP subject autosomal dominant mutation RPE65 .</brief_summary>
	<brief_title>Oral QLT091001 Retinitis Pigmentosa ( RP ) Subjects With Autosomal Dominant Mutation Retinal Pigment Epithelial 65 Protein ( RPE65 )</brief_title>
	<detailed_description />
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<mesh_term>Retinol acetate</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<criteria>Subjects RP cause autosomal dominant mutation RPE65 , diagnose ocular geneticist ophthalmologist . Subjects bestcorrected standard ETDRS visual acuity 3 letter well ( 20/800 Snellen equivalent ) visible photoreceptor outer segment OCT/FAF . Subjects clinically important abnormal physical finding Screening . Subjects take prescription investigational oral retinoid medication ( e.g. , Accutane/Roaccutane® Soriatane/Neotigason® ) within 6 month Day 0 subject tolerate previous oral retinoid medication exclude regardless time last exposure . Subjects history diabetes chronic hyperlipidemia , hepatitis , pancreatitis , cirrhosis . Subjects take supplement contain ≥10,000 IU vitamin A within 60 day Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>